On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
In this prospective, open, controlled, cross-sectional observational study patients with
psoriasis or IBD, who received either anti-TNF-alpha inhibitors or alternates (purine-, folic
acid analogues, phototherapy, fumaric ester, mesalazine) for their underlying disease were
included.
Anogenital HPV-induced lesions, mucosal HPV DNA and serological status of mucosal low-risk
(HPV6) and high-risk HPV (HPV16, HPV18) were determined.